Thymosin Alpha-1 Research Peptide

Yes. Every batch of Thymosin Alpha-1 is tested by an independent third-party laboratory using HPLC and MS-UPLC, confirming purity and mass identity before the batch is released. Pure Peptides does not test its own material.

It means Thymosin Alpha-1 is supplied for in-vitro laboratory research and for no other purpose, and must not be administered to humans or animals. Thymosin Alpha-1 is legal to purchase in the United States for in vitro and non-clinical laboratory research. Thymosin Alpha-1 is not a scheduled substance under the Controlled Substances Act. As a medicine it is known as thymalfasin and marketed under the brand name ZADAXIN; it is authorised in more than 30 countries outside the United States and Europe, according to its developers, and it holds no marketing authorisation from the FDA, the UK MHRA, or, beyond a single orphan drug designation, the European Medicines Agency. The material supplied here is a research-grade preparation, not that licensed medicine, and it holds no marketing authorisation. Sold strictly for qualified research use, not human or veterinary administration.

Thymosin Alpha-1 ships from US stock with cold-chain packaging and full tracking; orders placed before noon EST on business days are typically dispatched the same business day. On arrival, store the lyophilized powder at -20°C or below, dry and protected from light.

No. Thymosin Alpha-1 is a 28-amino-acid peptide with an acetylated N-terminus. Thymosin Beta-4 is a separate 43-amino-acid peptide, and TB-500 is a fragment associated with it. They share a family name and nothing else. Research findings for one say nothing about the others.

They disagree. A 2025 double-blind phase 3 trial in 1,089 patients found 28-day mortality of 23.4% against 24.1% on placebo, with no difference on any secondary or safety outcome. A 2013 single-blind trial in 361 patients found 26.0% against 35.0%, at marginal significance that changes with the statistical test applied. A 2025 meta-analysis of 11 trials found a significant pooled effect that was no longer significant when restricted to high-quality or multicentre trials. The Published Research tab reports all three.